Comparative Pharmacology
Head-to-head clinical analysis: AMARYL versus MICRONASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMARYL versus MICRONASE.
AMARYL vs MICRONASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonylurea that stimulates insulin secretion from pancreatic beta cells by binding to the sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, causing channel closure and calcium influx.
Stimulates insulin secretion from pancreatic beta cells by binding to sulfonylurea receptor (SUR1) on ATP-sensitive potassium channels, leading to membrane depolarization, calcium influx, and exocytosis of insulin.
Initial dose 1-2 mg orally once daily, titrated to target glucose. Maximum dose 8 mg daily.
Initial dose: 2.5-5 mg orally once daily with breakfast. Maintenance: 1.25-20 mg daily in single or divided doses. Maximum: 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours; clinically, dosing is once daily due to sustained glucose-lowering effect beyond half-life.
Terminal elimination half-life: 10 hours (range 7-20); clinical context: duration of action may be prolonged in renal impairment.
Approximately 60% excreted renally as metabolites (mainly M1 and M2) and 40% in feces; <1% excreted unchanged.
Renal: approximately 50% as metabolites and unchanged drug; biliary/fecal: approximately 50% as metabolites.
Category C
Category C
Sulfonylurea Antidiabetic
Sulfonylurea Antidiabetic